Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non-Small Cell Lung Cancer.

JCO precision oncology - 1 Aug 2024

Wang Huaying, Lin Lie, Liang Chuqiao, Pang Jiaohui, Yin Jiani C, Zhang Junli, Shao Yang, Sun Chengming, Guo Renhua

Abstract excerpt

PURPOSE: Next-generation sequencing (NGS) has enabled the detection of concomitant driver alterations in non-small cell lung cancer (NSCLC). However, the magnitude and clinical relevance of concomitant drivers remain to be explored. METHODS: We profiled concomitant driver alterations of EGFR+ NSCLC by using targeted NGS. The associated genomic and clinical features were analyzed and validated in an independent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to TSC2 gene

Share to High-Throughput Nucleotide Sequencing

Share to Lung Neoplasms

Share to Mutation

Source

Identifiers

PMID: 39102631
DOI: 10.1200/PO.23.00520

Genes

EGFR
MET
ERBB2
KRAS
BRAF
CD274
TP53
TSC2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non-Small Cell Lung Cancer.PMID 39102631Read ↗

Coexisting driver alterations in non-small cell lung cancer: Prevalence, clonal architecture, and impact on survival and progression.Semantic proximity Read ↗

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A ReviewSemantic proximity Read ↗

Concomitant driver mutations in advanced EGFR -mutated non-small-cell lung cancer and their impact on erlotinib treatmentSemantic proximity Read ↗

Co-Occurring Driver Genomic Alterations in Advanced Non-Small-Cell Lung Cancer (NSCLC): A Retrospective AnalysisSemantic proximity Read ↗

Concurrent driver mutations/rearrangements in non-small-cell lung cancer.Semantic proximity Read ↗

Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.Semantic proximity Read ↗

The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies?Semantic proximity Read ↗

Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non–Small-Cell Lung Cancer Harboring MET Exon 14 SkippingSemantic proximity Read ↗

TP53 co-mutations are associated with elevated PD-L1 expression and high tumor mutational burden in non-small cell lung cancer: insights from comprehensive genomic profilingSemantic proximity Read ↗

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic PathwaysSemantic proximity Read ↗

Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.Semantic proximity Read ↗

The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.